Literature DB >> 11803463

Delayed mammary gland involution in MMTV-AKT1 transgenic mice.

Scott Ackler1, Shakeel Ahmad, Christopher Tobias, Michael D Johnson, Robert I Glazer.   

Abstract

AKT1/protein kinase Balpha is a protein-serine/threonine kinase that regulates multiple targets involved in cell survival and cell cycle progression in a variety of cell types including breast cancer cells. To explore the role of Akt1 in mammary gland function and tumorigenesis, transgenic mice were generated that express human AKT1 under the control of the MMTV promoter. Virgin transgenic mice did not exhibit a dominant phenotype, but upon cessation of lactation, a notable delay in involution occurred compared to age-matched non-transgenic mice. The delay in involution coincided with increased hyperplasia as evidenced by an increased number of binucleated epithelial cells and a marked elevation in cyclin D1 expression in mammary epithelium. The delayed involution phenotype corresponded to increased phosphorylation of Thr308 in AKT1 and Ser136 in BAD, but not phosphorylation of Ser21 in GSK-3alpha. There was no evidence of mammary dysplasia or neoplasia during the lifespan of multiparous transgenic mice. These data suggest that AKT1 is involved in cell survival in the lactating and involuting mammary gland, but that overexpression of AKT1 alone is insufficient to induce transformation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803463     DOI: 10.1038/sj.onc.1205052

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

Review 1.  Apoptosis regulation in the mammary gland.

Authors:  K A Green; C H Streuli
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 2.  The molecular culprits underlying precocious mammary gland involution.

Authors:  Kate D Sutherland; Geoffrey J Lindeman; Jane E Visvader
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-03       Impact factor: 2.673

Review 3.  The beginning of the end: death signaling in early involution.

Authors:  Fiona O Baxter; Kevin Neoh; Maxine C Tevendale
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-03       Impact factor: 2.673

4.  Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1.

Authors:  Bradley A Creamer; Kazuhito Sakamoto; Jeffrey W Schmidt; Aleata A Triplett; Richard Moriggl; Kay-Uwe Wagner
Journal:  Mol Cell Biol       Date:  2010-04-12       Impact factor: 4.272

5.  Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Authors:  Yuzhi Yin; Hongyan Yuan; Xiao Zeng; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

6.  Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.

Authors:  Jeffrey W Schmidt; Barbara L Wehde; Kazuhito Sakamoto; Aleata A Triplett; Steven M Anderson; Philip N Tsichlis; Gustavo Leone; Kay-Uwe Wagner
Journal:  Mol Cell Biol       Date:  2014-01-27       Impact factor: 4.272

Review 7.  Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts.

Authors:  Julie A Wickenden; Christine J Watson
Journal:  Breast Cancer Res       Date:  2010-04-09       Impact factor: 6.466

8.  Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.

Authors:  Rachelle L Dillon; Richard Marcotte; Bryan T Hennessy; James R Woodgett; Gordon B Mills; William J Muller
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

Review 9.  Genetically engineered mouse models of PI3K signaling in breast cancer.

Authors:  Sjoerd Klarenbeek; Martine H van Miltenburg; Jos Jonkers
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

10.  Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes.

Authors:  Yingqiu Xie; Sanzhar Naizabekov; Zhanlin Chen; Tursonjan Tokay
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.